Krystal Biotech, Inc.
KRYS
$256.33
$6.172.47%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 33.95% | 54.51% | 116.09% | 247.53% | 473.02% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 33.95% | 54.51% | 116.09% | 247.53% | 473.02% |
| Cost of Revenue | 14.89% | 19.03% | 106.79% | 311.21% | 548.38% |
| Gross Profit | 35.36% | 57.36% | 116.78% | 243.64% | 468.12% |
| SG&A Expenses | 29.27% | 27.66% | 25.16% | 19.80% | 15.49% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 21.74% | 21.76% | 27.85% | 32.32% | 26.61% |
| Operating Income | 56.09% | 143.47% | 3,670.33% | 342.51% | 206.17% |
| Income Before Tax | 98.70% | 225.68% | 55.70% | 133.44% | 639.37% |
| Income Tax Expenses | -347.88% | -337.75% | 801.97% | 615.57% | 215.37% |
| Earnings from Continuing Operations | 129.74% | 279.80% | 38.50% | 116.86% | 715.58% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 129.74% | 279.80% | 38.50% | 116.86% | 715.58% |
| EBIT | 56.09% | 143.47% | 3,670.33% | 342.51% | 206.17% |
| EBITDA | 53.98% | 134.36% | 1,937.17% | 362.88% | 213.26% |
| EPS Basic | 127.79% | 275.94% | 35.29% | 118.34% | 1,619.49% |
| Normalized Basic EPS | 41.20% | 94.94% | 440.38% | 625.72% | 263.83% |
| EPS Diluted | 128.75% | 277.27% | 34.98% | 122.84% | 3,746.21% |
| Normalized Diluted EPS | 41.86% | 95.51% | 439.69% | 604.04% | 258.35% |
| Average Basic Shares Outstanding | 1.23% | 1.45% | 1.85% | 3.35% | 5.33% |
| Average Diluted Shares Outstanding | 0.83% | 1.43% | 2.37% | 4.96% | 7.84% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |